The Technion Research and Development Foundation (TRDF) connects the university’s research with industry and applied development. Its T3 technology-transfer unit handles commercialization of Technion technologies and patents. Two biomedical examples show different paths from research to impact: the basic science recognized by the 2004 Nobel Prize in Chemistry and Yoram Palti’s company Novocure.
What TRDF and T3 do
TRDF is a subsidiary of the Technion. The university describes its roles as supporting funded research, managing research-related legal and intellectual-property matters, and creating ties between researchers and industry. T3, a unit within TRDF, works on commercializing technologies and patents originating at the Technion, from patent registration through business development. These are the foundation’s stated functions, distinct from companies founded independently by alumni or professors. See TRDF’s account of its services.
Technology transfer gives a discovery a route toward development by identifying intellectual property and connecting it with partners able to advance it. It does not mean every research finding becomes a product. The university’s research overview describes TRDF as a link between academic research and business and industry.
A basic discovery recognized by the Nobel committee
Aaron Ciechanover and Avram Hershko, both at the Technion, shared the 2004 Nobel Prize in Chemistry with Irwin Rose of the University of California, Irvine. The prize recognized their discovery of ubiquitin-mediated protein degradation: cells attach ubiquitin to selected proteins and direct them for breakdown. The system helps regulate cellular processes. The Nobel committee’s scientific account of the discovery credits all three researchers and describes the work across the late 1970s and early 1980s.
From biophysics to a cancer treatment company
Yoram Palti, a professor emeritus of physiology and biophysics at the Technion, founded Novocure in 2000. The company developed Tumor Treating Fields, alternating electric fields applied at specific frequencies to disrupt cancer-cell division. Novocure’s company history describes Palti’s work and the development of the approach; its treatment use depends on the relevant cancer and approved clinical setting. This path joined academic expertise with company development. Novocure’s history identifies Palti as its founder and explains the treatment concept.
The Nobel-recognized discovery and Tumor Treating Fields are distinct examples: one advanced understanding of cell biology, while the other became the basis of a medical technology company. Both show how Technion research can extend beyond the laboratory through different routes.